Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $10
Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $8 to $10.
Read original at benzingaStocks · News reference
Cardiol Therapeutics Announces Publication Of Phase II MAvERIC Study Results In The Journal of the American Heart Association
The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment. The publication describes clinical findings in which CardiolRx™ was associated with rapid and sustained reductions in
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 14, 2026, 11:29 AM
- Checked
- Jul 14, 2026, 11:29 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
Read original at benzinga